AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2024862
Drug: Placebo, delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, delivered via ultrasonic nebulizer, 5 doses over 14 days followed by maintenance of one dose every 2 weeks.
Trial: 7416269
Drug: Hemodialysis, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodialysis, twice weekly for 10 weeks
Trial: 7416269
Drug: Sham dialysis,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dialysis, twice weekly for 10 weeks
Trial: 6697071
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml normal saline
Trial: 28866763
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (StnTx: two servings milk and milk products/day; meet PA guidelines plus weight-bearing PA three times/week)
Trial: 28866763
Drug: Modified treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified treatment (ModTx: four servings milk and milk products/day; meet PA guidelines plus daily weight-bearing PA)
Trial: 23578004
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg three times a day for 5 days
Trial: 16939522
Drug: Novel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel matrix transdermal delivery system of fentanyl
Trial: 16939522
Drug: Durogesic reservoir
RxNorm normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Durogesic reservoir formulation
Trial: 11485582
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of butylcyanoacrylate
Trial: 7522283
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg o.d.)
Trial: 7603076
Drug: Enalapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-20 mg o.d.)
Trial: 3250868
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ferrous sulphate
Trial: 3250868
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg riboflavin and 150 mg ascorbic acid
Trial: 23909402
Drug: L-carnitine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (900 mg/day)
Trial: 20962342
Drug: Dilute diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute diesel exhaust (particle concentration 300 μg/m³)
Trial: 18704484
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (1.7 MJ day(‐1) high-protein supplement composed of 50% valine, 35% leucine, and 15% isoleucine)
Trial: 17039422
Drug: metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin plus liraglutide
Trial: 1486457
Drug: Dopaminergic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic therapy (levodopa, bromocriptine)
Trial: 20708714
Drug: Micronutrient and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient and antioxidant preparation
Trial: 20708714
Drug: Standard multivitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multivitamins (identical appearing recommended daily allowance multivitamin and mineral preparation)
Trial: 16280697
Drug: HAART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART plus subcutaneous IL-2
Trial: 16280697
Drug: HAART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART plus intravenous IL-2
Trial: 12184060
Drug: Eprosartan (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (600 mg/day)
Trial: 12118904
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril (10 mg/day) and eprosartan (300 mg/day)
Trial: 10468077
Drug: Chewed buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewed buffered aspirin tablet (325 mg)
Trial: 10468077
Drug: Swallowed whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowed whole buffered aspirin tablet (325 mg)
Trial: 10468077
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin solution (Alka Seltzer)
Trial: 462483
Drug: Single test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single test dose of irradiation
Trial: 462483
Drug: Fractionated test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated test dose of irradiation
Trial: 25736134
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 mg atorvastatin calcium)
Trial: 9709756
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 0.1% (Voltaren)
Trial: 9709756
Drug: Prednisolone sodium
RxNorm normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone sodium phosphate 1% ophthalmic solution
Trial: 7977070
Drug: Sotalol (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (240 mg twice daily for 7 days)
Trial: 7977070
Drug: Amiodarone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (600 mg 3 times daily for 10 days)
Trial: 2535309
Drug: Phentolamine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine, 3 mg
Trial: 26508645
Drug: Breast augmentation
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast augmentation in the subglandular plane
Trial: 17351806
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate (600 mg)
Trial: 12605430
Drug: Intra-operative Photofrin-photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative Photofrin-photodynamic therapy (PDT)
Trial: 7543038
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg morphine
Trial: 10702454
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg morphine
Trial: 8447205
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% with epinephrine, 20 ml, intermittent 8-hourly bolus injections
Trial: 2943816
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (HBX‐R) administered IM at 10 micrograms, 3 doses (0, 1 month, 6 months)
Trial: 2943816
Drug: Plasma-derived hepatitis
RxNorm normalized name: Haptoglobulin 1/1 (Plasma Derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-derived hepatitis B vaccine (H‐B‐VAX) administered IM at 20 micrograms, 3 doses (0, 1 month, 6 months)
Trial: 31560577
Drug: Sports medicine
RxNorm normalized name: Mueller Sports Medicine Compression Glove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports medicine physicians
Trial: 31560577
Drug: Family/internal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family/internal medicine physicians
Trial: 29446377
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D)
Trial: 27431995
Drug: Daily trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily trimethoprim-sulfamethoxazole (TS) prophylaxis
Trial: 27431995
Drug: Weekly chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly chloroquine (CQ) prophylaxis
Trial: 27431995
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of standard of care TS prophylaxis
Trial: 24615137
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP)
Trial: 9583331
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment
Trial: 10389026
Drug: B-vitamins (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-vitamins (400 micrograms folic acid + 1.65 mg pyridoxine + 3 micrograms cyanocobalamin)
Trial: 9060347
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (current/daily routines)
Trial: 26352814
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin
Trial: 1650406
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Low-molecular-weight heparin and Unfractionated heparin)
Trial: 1650406
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin and Unfractionated heparin
Trial: 12452235
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg epidural morphine
Trial: 7104806
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg epidural morphine
Trial: 7104806
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (saline control)
Trial: 27409799
Drug: CHX solution
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX solution with SRP
Trial: 27409799
Drug: CHX gel
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHX gel with SRP
Trial: 21109344
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg
Trial: 31554005
Drug: Naftopidil 75
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 75 mg
Trial: 22929677
Drug: Detralex (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detralex (1,000 mg daily for 2 weeks prior and 4 weeks after endovascular treatment)
Trial: 22929677
Drug: Conventional compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional compression therapy (compression bandages or medicinal knitted fabric)
Trial: 15663066
Drug: Message campaign
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Message campaign about hand hygiene and availability of gel hand sanitizer
Trial: 12858132
Drug: Topiramate (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (initial dose of 25 mg/day to a target dose of 100 mg BID)
Trial: 10235193
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (2 tablets of Pepto-Bismol, positive control)
Trial: 9074893
Drug: Paracetamol tablets
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol tablets (two lots)
Trial: 1751620
Drug: MCPP (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCPP (0.25 mg/kg)
Trial: 7047172
Drug: Metergoline 4
RxNorm normalized name: metergoline 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline 4 mg tid for 7 days
Trial: 7047172
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg bid for 7 days
Trial: 7047172
Drug: Metergoline (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline (continued treatment for 7 days)
Trial: 7047172
Drug: Bromocriptine (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (continued treatment for 7 days)
Trial: 21993890
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium intake (300 mmol sodium/day; 17.5 g salt/day)
Trial: 21993890
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium intake (30 mmol sodium/day; 1.8 g salt/day)
Trial: 18685353
Drug: Lidocaine patches
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patches
Trial: 11145439
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) induction treatment
Trial: 11145439
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) maintenance treatment
Trial: 2857610
Drug: Guanfacine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (alpha 2‐agonist)
Trial: 2857610
Drug: Idazoxan (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idazoxan (alpha 2‐antagonist)
Trial: 22950522
Drug: GLPG0259 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0259 single ascending doses (1.5-150 mg)
Trial: 22950522
Drug: GLPG0259 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0259 multiple doses (20 and 50 mg once daily)
Trial: 22950522
Drug: GLPG0259 multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0259 multiple doses (25-75 mg once daily for 14 days)
Trial: 22950522
Drug: GLPG0259 solid
RxNorm normalized name: CORYDALIS SOLIDA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0259 solid dosage form
Trial: 17511187
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous pethidine
Trial: 10513040
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine in treating coronary artery disease (CAD)
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin 50 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin 100 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin 5 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin 10 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin 25 mg
Trial: 2126726
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 300 mg
Trial: 2126726
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin 50 mg
Trial: 2126726
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and glycine formulation 100 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin doses above 100 mg
Trial: 2126726
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release aspirin doses of 50 mg and below
Trial: 30865629
Drug: Small-quantity lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-quantity lipid-based nutrient supplements (SQ-LNS) given to mothers and children during the first 1,000 days
Trial: 27919901
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 IV 50 mg
Trial: 27919901
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 IV 100 mg (once weekly for 2 weeks)
Trial: 27919901
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 IV 200 mg (once weekly for 2 weeks)
Trial: 27919901
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD101 IV 400 mg (once weekly for 3 weeks)
Trial: 25145377
Drug: Varenicline 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 2 mg single dose
Trial: 21808760
Drug: Brånemark (Nobel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brånemark (Nobel Biocare) implants
Trial: 20874829
Drug: Both implant
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both implant systems
Trial: 11934971
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate (GTN) 2% ointment applied for 1 minute
Trial: 11934971
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied for 1 minute
Trial: 11934971
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated finger)
Trial: 9469350
Drug: I.V.‐oral regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V.‐oral regimen
Trial: 7612061
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 150 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Trial: 7612061
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 300 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Trial: 2242456
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily (increased to a maximum of 200 micrograms daily)
Trial: 38176
Drug: None of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None of the drugs
Trial: 23872125
Drug: C500 (C0+500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C500 (C0+500 g/t aflatoxin biodegradation preparations)
Trial: 23872125
Drug: C1000 (C0+1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1000 (C0+1000 g/t aflatoxin biodegradation preparations)
Trial: 23872125
Drug: M500 (M0+500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M500 (M0+500 g/t aflatoxin biodegradation preparations)
Trial: 23872125
Drug: M1000 (M0+1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M1000 (M0+1000 g/t aflatoxin biodegradation preparations)
Trial: 23872125
Drug: M2000 (M0+2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2000 (M0+2000 g/t aflatoxin biodegradation preparations)
Trial: 21674848
Drug: gabapentin-NSAID-morphine
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gabapentin-NSAID-morphine
Trial: 11041313
Drug: Morphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (5 and 10 mg/70 kg)
Trial: 9347207
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug (NSAID) after the first dose of misoprostol
Trial: 9347207
Drug: No nonsteroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nonsteroidal anti-inflammatory drug after the first dose of misoprostol
Trial: 9347207
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Trial: 9347207
Drug: No nonsteroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nonsteroidal anti-inflammatory drug after the second dose of misoprostol
Trial: 8111210
Drug: Foot reflexotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexotherapy (FR) plus conventional Western medicine (hypoglycemic agent)
Trial: 3089360
Drug: Salt added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt added to lentils (4.25 g)
Trial: 3089360
Drug: Salt added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt added to bread (4.25 g)
Trial: 17576868
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg
Trial: 22362559
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 1 mg/kg followed by TNK-tPA
Trial: 22362559
Drug: Supplemental IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental IV enoxaparin 0.3 mg/kg
Trial: 22362559
Drug: IV enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV enoxaparin 0.3 mg/kg
Trial: 18561117
Drug: Ciclesonide 200
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 200 microg once daily